Predictive Oncology Inc. (NASDAQ:POAI) Q2 2023 Earnings Call Transcript

Raymond Vennare: I will say, Michael, that we’ve mentioned CRH several times, right? And I think everyone is very well attuned to the significance of that relationship. And we are actively — I’m here at the laboratory right now. I’m doing a call from the laboratory, and we are working on that project as we speak. So no one is more anxious than we are to move that forward as quickly as possible. But as Bob said, we are doing on our end, certainly everything we can do. We have to work through on the other end, how long it takes our partners, our customers, our collaborators actually get us what we need and give the approvals and just keep the projects moving.

Operator: Thank you. There are no further questions. I would like to turn the floor back over to Raymond for closing comments.

Raymond Vennare: Okay. Well, thank you, everyone. That concludes today’s call. We hope that you can take away from this call the fact that all of us at predictive oncology are very excited about the growth trajectory of the company. What’s been happening in the last few months, much of that what we’ve been talking about for the last few months is finally coming to fruition. So in the coming quarters, I would anticipate more collaborations and partnerships with some of the leading drug developers and research and academic institutions. They are critical to the process. We’re also very excited to play an important role in the discovery of new oncology drugs. That’s certainly part of the relationship with CRH which we believe and everyone on this call, I truly believe understands the benefits of the patients, but will also create enduring value for our shareholders.

So I want to thank you all for your support, and I look forward to the third quarter update, and I wish you all a good day and a good evening. Thank you.

Operator: This concludes today’s teleconference. You may disconnect your lines at this time. Thank you for your participation.